Glimepiride Aurobindo (Glimepiride)

Glimepiride Aurobindo is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve target glycemic control.

• Used as monotherapy in patients with mild to moderate hyperglycemia.
• Added to other oral antidiabetic agents when additional glucose lowering is needed.
• May be prescribed after metformin failure or intolerance.
• Helps reduce fasting and post‑prandial blood glucose levels.
• Often part of a stepwise treatment algorithm for type 2 diabetes.

The safety profile of glimepiride includes both frequent, less severe reactions and rare, potentially serious events.

Common

• Mild hypoglycemia, especially when meals are missed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain.
• Fatigue or tiredness.
• Transient visual disturbances.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as rash, itching, swelling, or angioedema.
• Hematologic abnormalities like leukopenia, neutropenia, or thrombocytopenia.
• Hepatic dysfunction indicated by elevated liver enzymes.

Before initiating glimepiride therapy, clinicians should evaluate several clinical factors to minimize risks.

• Assess renal and hepatic function; dose adjustments may be required in impairment.
• Review history of hypoglycemia; patients with prior episodes need close monitoring.
• Use caution in elderly patients due to increased sensitivity to glucose lowering.
• Avoid use during pregnancy and lactation unless benefits outweigh risks.
• Consider potential cardiovascular disease; sulfonylureas may affect ischemic preconditioning.
• Evaluate concomitant use of beta‑blockers that can mask hypoglycemia symptoms.
• Ensure patients understand the importance of regular meals to prevent hypoglycemia.

Glimepiride can interact with various medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glimepiride plasma levels.
• Disulfiram‑like drugs (e.g., chlorpropamide) that potentiate hypoglycemic action.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, which may reduce glucose control.
• Corticosteroids, which can increase blood glucose and counteract the drug’s effect.
• Anticoagulants such as warfarin, as glimepiride may affect INR stability.